RxDoctor Payments Data

Joseph Becker, APRN

Family · Paducah, KYNPI 1336770759

Payments from drug & device makers

$1,974in general payments, 2019–2025

Across 107 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$550
  • Bayer$458
  • OPKO Pharmaceuticals, LLC$245
  • Akebia Therapeutics Inc$222
  • Amgen$111
  • Boehringer Ingelheim$98
  • plus $290 from 9 others

What the payments were for

  • Food & beverage$1,69286%
  • Education$28214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,974 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$84,275
Medicare patients
410
Services billed
913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol76$65,063
AuryxiaFerric Citrate18$44,093
KerendiaFinerenone69$43,627
JardianceEmpagliflozin32$19,899
RayaldeeCalcifediol14$16,360
SpsSodium Polystyrene Sulfon/Sorb25$10,125
LokelmaSodium Zirconium Cyclosilicate13$6,916
Cinacalcet Hcl22$5,659
Clonidine25$3,705
Calcitriol197$2,565
Hydralazine Hcl92$1,171
Losartan Potassium112$738
Amlodipine Besylate132$658
Allopurinol97$535
Lisinopril126$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$550$71,97989 claims
Akebia Therapeutics IncAuryxia$222$44,09318 claims
BayerKerendia$458$43,62769 claims
Boehringer IngelheimJardiance$98$19,89932 claims
OPKO Pharmaceuticals, LLCRayaldee$245$16,36014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →